Benzinga

搜索文档
Salesforce Posts Q1 Beat As AI Crosses $1B, But How Concerned Should Investors Be About Margins?
Benzinga· 2025-05-29 23:38
Shares of Salesforce Inc CRM tanked in early trading on Thursday, despite the company Wednesday reporting strong first-quarter results.Here are some key analyst takeaways.Goldman Sachs analyst Kash Rangan reaffirmed a Buy rating, while lifting the price target from $340 to $385.Needham analyst Scott Berg maintained a Buy rating and price target of $400.JPMorgan analyst Mark Murphy reiterated an Overweight rating and price target of $380.Bank of America Securities analyst Brad Sills reaffirmed a Buy rating a ...
These Analysts Slash Their Forecasts On HP Following Downbeat Earnings
Benzinga· 2025-05-29 23:32
HP Inc HPQ reported weaker-than-expected earnings for the second quarter on Wednesday.HP reported second-quarter revenue of $13.22 billion, beating analyst estimates of $13.15 billion. The company reported second-quarter adjusted earnings of 71 cents per share, missing estimates of 80 cents per share, according to Benzinga Pro."In Q2, we delivered solid revenue growth, led by strong Commercial performance in Personal Systems and continued momentum behind our future of work strategy," said Enrique Lores, pre ...
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course
Benzinga· 2025-05-29 23:25
Intellia Therapeutics Inc NTLA said on Wednesday that a single, recent, asymptomatic patient has had grade 4 (severe) liver transaminase elevations (liver enzymes) based on laboratory tests in its Phase 3 MAGNITUDE study.The trial is evaluating nexiguran ziclumeran (nex-z, also known as NTLA-2001) in transthyretin amyloidosis with cardiomyopathy.These elevations appear to be resolving without hospitalization or medical intervention and have fallen to grade 3 ALT and grade 2 AST elevations.The company has en ...
ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital
Benzinga· 2025-05-29 23:15
ORIC Pharmaceuticals Inc. ORIC released preliminary efficacy and safety data on Wednesday from its ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC).Preliminary activity analysis:59% of patients (10/17) achieved a PSA50 response and nearly all patients with a PSA50 response were confirmed one month later, for a confirmed PSA50 response rate of 47% (8/17), which does not include one addi ...
These Analysts Revise Their Forecasts On Salesforce Following Q1 Results
Benzinga· 2025-05-29 21:34
Salesforce Inc CRM reported better-than-expected first-quarter financial results after the market close on Wednesday.Salesforce reported first-quarter revenue of $9.83 billion, beating the consensus estimate of $9.75 billion. The company reported first-quarter adjusted earnings of $2.58 per share, beating analyst estimates of $2.55 per share, according to Benzinga Pro."We've built a deeply unified enterprise AI platform — with agents, data, apps and a metadata platform — that is unmatched in the industry. W ...
Best Buy Falls Short: Sales, Earnings Miss As Tariff Pressures Mount
Benzinga· 2025-05-29 21:31
Best Buy Co Inc BBY is trading lower Thursday after the retailer’s first-quarter 2026 earnings fell short of expectations.The company’s first-quarter sales fell around 1% (comparable sales fell 0.7%) year over year to $8.77 billion. It missed the analyst consensus estimate of $9.22 billion.Domestic revenue of $8.13 billion decreased 0.9%, primarily due to a 0.7% decline in comparable sales.The largest drivers of the comparable sales decline on a weighted basis were home theater, appliances, and drones, part ...
PepGen Abandons Duchenne Program, Shifts Spotlight To Another Rare Disease Candidate
Benzinga· 2025-05-29 21:19
PepGen Inc. PEPG announced on Wednesday that it will focus on advancing its myotonic dystrophy type 1 (DM1) program, currently in Phase 2 clinical development.The company voluntarily discontinued the development of PGN-EDO51 and intends to wind down all Duchenne muscular dystrophy (DMD)-)-related research and development activities.The decision is based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study of PGN-EDO51 in DMD patients amenable to exon 51 skipping.In ...
Costco Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga· 2025-05-29 20:34
Costco Wholesale Corporation COST will release its third-quarter earnings results after the closing bell on Thursday, May 29.Analysts expect the Issaquah, Washington-based company to report quarterly earnings at $4.23 per share, up from $3.78 per share in the year-ago period. Costco projects to report quarterly revenue at $63.1 billion, compared to $58.52 billion a year earlier, according to data from Benzinga Pro.The company beat revenue estimates in the second quarter, but has only beaten analyst estimate ...
Productivity Clashes With Premium Valuations For Direxion's PLTR-Focused Bull And Bear Funds
Benzinga· 2025-05-29 20:03
Easily one of the most dominant enterprises in recent memory is Palantir Technologies Inc. PLTR. A big data analytics specialist, Palantir has been a massive beneficiary of the boom in artificial intelligence. Since the start of this year, PLTR stock has gained nearly 64% of equity value, easily leapfrogging the Nasdaq Composite index, which is down 1% during the same period. Still, valuation concerns impose a dark cloud over PLTR's prospects.On the business front, it's difficult to argue against Palantir's ...
Top Wall Street Forecasters Revamp Kohl's Expectations Ahead Of Q1 Earnings
Benzinga· 2025-05-29 17:03
Kohl’s Corporation KSS will release its first-quarter earnings results before the opening bell on Thursday, May 29.Analysts expect the Menomonee Falls, Wisconsin-based company to report a quarterly loss at 22 cents per share, versus a year-ago loss of 24 cents per share in the year-ago period. According to data from Benzinga Pro, Kohl’s projects to report quarterly revenue at $3.06 billion, compared to $3.18 billion a year earlier.On May 15, Kohl’s announced the pricing of private offering of $360 million o ...